Nasus Pharma (NSRX): SEC Form 4 filed by Chief Executive Officer Teleman Dan Benjamin
Stocks in this Quantisnow insightHealth Care
Historical context for NSRX
Across the 17 sessions after earlier NSRX headlines, the stock closed higher 7 times and lower 8 times, with a median move of 4.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NSRX | SPY |
|---|---|---|---|
| Jun 22, 2026 | Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum | +1.6% | -0.3% |
| Jun 9, 2026 | Nasus Pharma Announces Positive Results from Preclinical Pharmacokinetic and Safety Study of Intranasal Ondansetron (NS003) | -0.3% | -0.3% |
| Jun 1, 2026 | Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis | -0.6% | +0.3% |
| May 1, 2026 | Nasus Pharma to Participate in Upcoming Investor Conferences | +1.9% | +0.3% |
| Mar 25, 2026 | Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update | +10.8% | +0.6% |
| Mar 19, 2026 | BriefCast Publishes Transcript: Nasus Pharma NS002 Phase 2 Positive Topline Results Webinar Transcript | -5.3% | -0.2% |
Earlier insider filings at NSRX
Quantisnow market dataAMEX
NSRX
Nasus Pharma Ltd.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2025
Get push alerts for NSRX
Full NSRX profile on Quantisnow Follow NSRX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time